Posts
April 18 2012
ParkerVision announced the closing of their Registered Direct in the amount of $1,963,501. EG&S acted as counsel to the placement agent.
April 11 2012
Dipexium Pharmaceuticals, LLC, a private biotechnology company, closed a venture private placement of Series A membership interests and warrants in an amount of over $500,000. EG&S acted as counsel to Dipexium.
April 11 2012
DARA BioSciences, Inc. announced the closing of their Registered Direct offering in the amount of $10,250,000. EG&S acted as counsel to the placement agent.
April 04 2012
Ellenoff Grossman & Schole LLP was ranked #1 for placement agent representation in PIPE transactions (by number of transactions) for the first quarter of 2012.
April 04 2012
Morria Biopharmaceuticals, PLC announced the closing of their PIPE offering in the amount of $1,100,000. EG&S acted as counsel to the investor.
March 30 2012
Elephant Talk Communications Corp. (Amex: ETAK) issued certain Senior Secured Convertible Notes in the principal amount of $8,800,000 to accredited investors. EG&S acted as issuer's counsel.
March 30 2012
NeoStem, Inc. (NYSE Amex: NBS) sold 15,000,000 units at $0.40 per unit with $6 million in gross proceeds in an underwritten offering pursuant to the NeoStem's shelf registration statement . Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. NeoStem has also granted Maxim a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. EG&S acted as Maxim’s counsel.
March 30 2012
Epicept Corporation announced the closing of their Registered Direct offering in the amount of $1,065,000. EG&S acted as counsel to the placement agent.